N/A N=34 Positive Airway Pressure Program
Sleep Apnea, Obstructive
Primary: Participant Providing Feedback — 26 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=164 Positive Pressure Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Apnea-Hypopnea Index — 6.09; 3.54; 3.24; 1.26 events/hour — p=0.3
Phase 3 N=1,105 Apnea Positive Pressure Long-Term Efficacy Study
Lung Diseases · Sleep Apnea Syndromes · Sleep
Primary: Effect of CPAP on Neurocognitive Function: E/F Function- SWMT-OMD — 0.035; -0.074; 0.072; 0.018 score on a scale — p=0.0074
N/A N=32 Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 2.4 events per hour
N/A N=25 Servo-Ventilation In-lab PSG Evaluation
Sleep Apnea Syndromes
Primary: Average Apnea Hypopnea Index Among Different Polysomnography Devices. — 18.4; 25.4; 24.1; 19.2 events per hour
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
N/A N=150 TPAP for Comfort in OSA
Obstructive Sleep Apnea
Primary: CPAP v TPAP Patient Preference at 9 cmH2O Baseline Pressure, TPAP Drop 2+2 cmH2O — 69.3 percentage of total participants
N/A N=194 Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
Asthma
Primary: Methacholine Reactivity — 2.13; 1.48; 1.44; 1.60 mg/mL — p=0.51
Phase 2 N=12 Sleep Apnea Treatment With Expiratory Resistance(Provent™)
Sleep Apnea, Obstructive
Primary: Change in AHI — 45; -15.8 events/h
N/A N=78 CPAP vs ASV for Insomnia
Insomnia · Sleep-Disordered Breathing
Primary: Insomnia Severity Index — 9.29; 13.21 units on a scale
N/A N=21 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
N/A N=15 Upper Airway Physical Therapy for the Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea Syndrome
Primary: Delta of Apnea Hypopnea Index (AHI) as Measured by Polysomnography (PSG) — 4.27 events per hour
N/A N=270 Self-Management of Continuous Positive Airway Pressure Settings
Obstructive Sleep Apnea
Primary: Treatment Adherence — 2.1; 2.2 Hours per night
N/A N=156 Continuous Positive Airway Pressure (PAP) Titration and Treatment Versus Auto-adjusting PAP Treatment for Sleep Apnea
Obstructive Sleep Apnea
Primary: Positive Airway Pressure Adherence (Nightly Use of Treatment) — 3.99; 4.45 hours — p== 0.27
N/A N=241 Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed Obstructive Sleep Apnea (OSA) Patients
Obstructive Sleep Apnea
Primary: CPAP Adherence — 3.6; 4.0 hours per night
N/A N=22 Combination Therapy to Treat Sleep Apnea
Sleep Apnea, Obstructive
Primary: Model Prediction of Absence/Presence of OSA: Ventilation That Causes an Arousal From Sleep (Varousal) — 5.7; 5.2 L/min — p=0.05
N/A N=49 Evaluation of Treatment Efficacy and Comfort of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea.
Obstructive Sleep Apnea (OSA)
Primary: PAP Treatment Efficacy — 4.2; 4.0 Events per hour
N/A N=21 Adjustment of Mask Pressure, for Bilevel Positive Airways Pressure Therapy, by Automated Algorithm
Respiratory Insufficiency · Sleep Disordered Breathing
Primary: Index of Apneoas Plus Hypopnoeas Per Hour of Sleep (AHI) — 1.3; 1.7 Events per hour of sleep
N/A N=59 Modulation Of Airway Reactivity With Chronic Mechanical Strain
Asthma
Primary: Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2) — 3.0; 3.2; 5.3; 4.3 mg/mL
N/A N=33 Revised Algorithm for Next Generation DeVilbiss Healthcare AutoAdjust Continuous Positive Airway Pressure (CPAP)
Obstructive Sleep Apnea
Primary: % Agreement Between Reviewer and Machine Pressure Settings During Sleep Study — 92.2 percentage of agreement
Phase 3 N=38 Astral VAPS AutoEPAP Clinical Trial
Upper Airway Obstruction · Respiratory Insufficiency · Respiratory Failure
Primary: Oxygen Desaturation Index 4% (ODI4%) — 3.16; 7.61 events per hour — p=0.0134
Phase 3 N=10 Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD · OSA
Primary: Control of Nocturnal Hypoventilation — 6.5; 6.7 kPa
N/A N=20 Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy
Obstructive Sleep Apnea
Primary: Hours Used — 146.9; 141.9 Total Hours Used
N/A N=15 Comparing Auto-adjustable Positive Airway Pressure to Continuous Positive Airway Pressure in Children With Sleep Apnea
Obstructive Sleep Apnea
Primary: Difference Between Optimal Pressure (cm H2O) Derived From APAP run-in Period Versus Result of CPAP Titration Study — 7.3; 9.4 cmH2O
Phase 1 N=118 Tailored Intervention to Promote Positive Airway Pressure Adherence
Sleep Apnea, Obstructive · Patient Compliance
Primary: Nightly CPAP Use — 6.4; 5.8 hours/night — p=0.20
N/A N=20 Comparison of Auto-Adjusting Positive Airway Pressure Devices
Obstructive Sleep Apnea
Primary: Mean Apnoea-Hypopnoea-Index (AHI) — 6.21; 7.45 events/hour — p=0.537
N/A N=90 AVAPS-AE Efficacy Study
Obesity Hypoventilation Syndrome
Primary: Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) — 47.1; 51.8; 50.7; 40.7 mmHg
N/A N=35 The Effectiveness of SensAwake™ for Continue Positive Airway Pressure Treatment of Obstructive Sleep Apnea Patients
Obstructive Sleep Apnea
Primary: Compliance of Auto-CPAP Therapy — 41.8; 39.7 percentage of nights
N/A N=146 Reducing Heart Failure Re-admissions by Enhancing Sleep Apnea Treatment Adherence
Congestive Heart Failure · Sleep Apnea Syndromes
Primary: Number of Participants Adhering to Positive Airway Pressure (PAP) — 5; 3 Participants — p=0.72
N/A N=43 Auto-PAP Therapy For Improved Fetal Growth
Obstructive Sleep Apnea · Pregnancy
Primary: Number of Participants With Slowing of Fetal Growth by 33% or More During the Last Trimester — 8; 8 Participants — p=0.92